Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy

Joyce K. Hwang, Neeraj Agarwal, James Brugarolas, Tian Zhang

Research output: Contribution to journalArticlepeer-review

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalClinical Cancer Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy'. Together they form a unique fingerprint.

Cite this